OIS@AAO 2016

vicken-karageozian

Allegro’s Karageozian

By Mario Admin | December 9, 2016

Vicken Karageozian, MD, president and chief medical officer, Allegro Ophthalmics, shares how Allegro has “taken a lot of risk out of the equation” after reporting…

Read More
Kevin Waltz

Eye Surgeon Walz Discusses Role in Mynosys Pivotal Trial

By Mario Admin | December 9, 2016

Kevin Waltz, MD, partner, Eye Surgeons of Indiana, Mynosys, explains how the company’s Zepto device helps create the “round, consistent” anterior lens capsulotomy in nearly…

Read More
Bill Burns

Encore CEO Burns Hopes to Get the Drop on Presbyopia

By Mario Admin | December 9, 2016

Bill Burns, president and CEO, Encore Vision, introduces OIS to Encore Vision, which has the “sole purpose” of developing a treatment for presbyopia. Burns says…

Read More

TearScience’s Boorady Touts LipiFlow’s Duration

By Mario Admin | December 9, 2016

Joseph Boorady, president and CEO, TearScience, shares details on recent studies that demonstrated LipiFlow’s ability to deliver long-term relief for dry eye sufferers. He also…

Read More
Bernhard Gunther

Novaliq’s Günther Discusses New Role

By Mario Admin | December 9, 2016

Bernhard Günther, managing director and co-founder, Novaliq GmbH, tells OIS-TV about Novaliq’s new CEO, Christian Roesky, PhD. Günther will assume the role of chief innovation…

Read More

Opthea’s Baldwin Gives Update on Clinical Data for OPT-302

By Mario Admin | December 9, 2016

Megan Baldwin, PhD, CEO and managing director, Opthea Ltd., introduces OPT-302, a new vehicle for targeting the VEGF pathway and wet age-related macular degeneration (AMD).…

Read More
Jim Mazzo

Zeiss’ Mazzo Says He’s Having Fun at Zeiss

By Mario Admin | December 9, 2016

Jim Mazzo, global president of ophthalmic devices, Carl Zeiss Meditec, explains why ophthalmology continues to draw interest from new players. He also reveals how he’s…

Read More
John Kilcoyne

ReVision’s CEO Updates OIS on Raindrop

By Mario Admin | December 9, 2016

John Kilcoyne, president and CEO, ReVision Optics, shares the company’s plans for a commercial rollout of Raindrop, the firm’s promising corneal inlay. Participant: John Kilcoyne…

Read More
Amar Sawhney

Ocular Therapeutix’s Sawhney Discusses Regeneron, FDA

By Mario Admin | December 9, 2016

Amar Sawhney, president, CEO, and chairman of Ocular Therapeutix, gives details on his company’s new collaboration with Regeneron to develop a sustained-release formulation of the…

Read More
Vince Anido

Aerie’s Anido Praises FDA Consistency

By Mario Admin | December 9, 2016

Vince Anido, PhD, CEO and chairman, Aerie Pharmaceuticals, sees hopeful signs in the FDA’s process to review combination therapies. This positioning could benefit Aerie in…

Read More

A View of the Public Ophthalmology Market & Exit Trends

By Mario Admin | December 6, 2016

The IPO market in ophthalmology may have cooled off last year, but that only mirrored what’s happened in healthcare overall. In this video from OIS@AAO…

Read More

Norris Delivers Updates, Predictions on Private Financings

By Mario Admin | December 6, 2016

Jonathan Norris, managing director at Silicon Valley Bank, delivered his overview of private investing in health care in 2016. Among the high points: Investments in…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.